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OBJECTIVE—The activation of AMP-activated protein kinase
(AMPK) has been reported to improve endothelial function.
However, the targets of AMPK in endothelial cells remain poorly
deﬁned. The aim of this study was to test whether AMPK
suppresses the degradation of GTP-cyclohydrolase (GTPCH I), a
key event in vascular endothelial dysfunction in diabetes.
RESEARCH DESIGN AND METHODS—Both human umbili-
cal vein endothelial cells and aortas isolated from streptozotocin-
injected diabetic mice were assayed for phospho-AMPK
(Thr172), GTPCH I, tetrahydrobiopterin (BH4), and endothelial
functions.
RESULTS—Oral administration of metformin (300 mg  kg
1 
day
1, 4 weeks) in streptozotocin-injected mice signiﬁcantly
blunted the diabetes-induced reduction of AMPK phosphoryla-
tionatThr172.Metformintreatmentalsonormalizedacetylcholine-
induced endothelial relaxation and increased the levels of
GTPCH I and BH4. The administration of AICAR, an AMPK
activator, or adenoviral overexpression of a constitutively active
mutant of AMPK abolished the high-glucose–induced (30 mmol/l)
reduction of GTPCH I, biopeterins, and BH4 but had no effect on
GTPCH I mRNA. Furthermore, AICAR or overexpression of
AMPK inhibited the high-glucose–enhanced 26S proteasome
activity. Consistently, inhibition of the proteasome by MG132
abolished high-glucose–induced reduction of GTPCH I in human
umbilical vein endothelial cells. Further, aortas isolated from
AMPK2
/ mice, which exhibited elevated 26S proteasome
activity, had reduced levels of GTPCH I and BH4. Finally, either
administration of MG132 or supplementation of L-sepiapterin
normalized the impaired endothelium-dependent relaxation in
aortas isolated from AMPK2
/ mice.
CONCLUSIONS—We conclude that AMPK activation normal-
izesvascularendothelialfunctionbysuppressing26Sproteasome-
mediated GTPCH I degradation in diabetes. Diabetes 58:1893–
1901, 2009
T
he most important factor for the maintenance of
vascular homeostasis is nitric oxide (NO), de-
rived from L-arginine in the catalysis of endothe-
lial nitric oxide synthase (eNOS). Many studies
have indicated that diabetes alters the metabolism and
function of endothelium in ways that could lead to vascu-
lar injury (1). In diabetes, the function of eNOS is altered
such that the enzyme produces superoxide anion (O2
–)
rather than NO (2). This phenomenon is referred to as
eNOS uncoupling and has been reported to play a causal
role in diabetes-enhanced endothelial dysfunction (3,4).
Several studies (5) have suggested that deﬁciency of
tetrahydrobiopterin (BH4), an essential cofactor for eNOS,
transforms eNOS into an oxidant-producing enzyme, lead-
ing to the production of O2
– and/or peroxynitrite
(ONOO
–).
Intracellular BH4 levels are dictated by a balance of de
novo synthesis, BH4 oxidation, and recycling of BH2 to
BH4 (6). De novo synthesis of BH4 is controlled by GTP
cyclohydrolase I (GTPCH I), a homodecameric protein
consisting of 25 kDa subunits in mammalian cells (7). As
the ﬁrst enzyme in the biosynthetic pathway of BH4,
GTPCH I is constitutively expressed in endothelial cells
and critical for the maintenance of BH4 levels and NO
synthesis. Indeed, acute inhibition of GTPCH I uncouples
eNOS, induces endothelial dysfunction, and elevates blood
pressure in vivo (8). Further, our recent study (9) suggests
that hyperglycemia uncouples eNOS by reducing the levels
of GTPCH I and BH4.
Proteasomes provide a major pathway of intracellular
protein degradation in mammalian cells (10–12). Although
proteasomes can degrade proteins by ubiquitin-
independent processes, they are mostly involved in the
ATP- and ubiquitin-dependent pathway of protein degra-
dation (13). The 26S proteasome complex consists of both
the 20S catalytic core, where the proteins are degraded,
and 19S complex, a regulatory subunit composed of at
least 19 different subunits that form a lid- and a base-like
structure; the lid provides the binding sites for poly-
ubiquitinated substrates and a deubiquitinating activity
involved in the recycling of ubiquitin moieties upon sub-
strate degradation; the base includes six ATPases that
interact with the 20S proteolytic core. The ATPases have
chaperone functions and are required for the unfolding of
substrates and their translocation into the 20S proteolytic
chamber (14,15). Therefore, intracellular protein degrada-
tion by the proteasome is a highly energy-demanding
process and, thus, it is expected that under conditions of
energy depletion this process should be tightly regulated.
The possible role of the ubiquitin proteasome system in
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DIABETES, VOL. 58, AUGUST 2009 1893the development of atherosclerosis in diabetes has been
addressed (16,17).
The AMP-activated protein kinase (AMPK) is a hetero-
trimeric protein composed of , , and  subunits. The 
(1 and 2) subunit imparts catalytic activity, whereas the
other subunits maintain the stability of the heterotrimer
complex (18). Activation of AMPK requires the phosphor-
ylation of AMPK at Thr172 in the activative loop of the 
subunit (19), and is mediated by at least two kinases,
Peutz-Jeghers syndrome kinase LKB1 (20) and Ca
2/
calmodulin-dependent protein kinase kinase (21). AMPK is
considered an “energy gauge,” which becomes activated
when intracellular AMP increases and/or ATP decreases.
Recently, Rosa Viana et al. (22) reported that AMPK
suppresses proteasome-dependent protein degradation in
vitro.Asourearlierstudy(9)demonstratedthatproteasome-
dependent GTPCH I degradation is key for diabetes-
induced endothelial dysfunction, we reasoned that AMPK
activation might alleviate diabetic endothelial dysfunction
by suppressing proteasome-dependent GTPCH I degrada-
tion. Here, we report that pharmacological or genetic
activation of AMPK reversed endothelial dysfunction by
suppressing GTPCH I degradation.
RESEARCH DESIGN AND METHODS
A full description of materials, animals, and methods used, including cell
culture, gene transfection to HUVECs, measurement of biopterins, detections
of NO and reactive oxygen species (ROS), streptozotocin (STZ)-induced
diabetes in mice, 26S proteasome activity assay, immunoprecipitation and
Western blot analysis, reverse-transcription PCR for GTPCH I, and organ
chamber, can be found in the online-only data supplement available at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-0267.
Gene transfection in HUVECs. Ad-GFP, a replication-defective adenoviral
vector expressing green ﬂuorescence protein (GFP), was used as control. An
adenoviral vector expressing a dominant-negative mutant of AMPK (AMPK-
DN) was constructed from AMPK bearing a mutation altering lysine 45 to
arginine (K45R), as described previously (23). To generate an adenoviral
vector expressing a constitutively active mutant of AMPK (AMPK-CA), a rat
cDNA encoding residues 1–312 of AMPK and bearing a mutation of threonine
172 to aspartic acid (T172D) was subcloned into a shuttle vector (pShuttle
CMV [cytomegalovirus]).
STZ-induced diabetes in mice. A low-dose STZ-induction regimen was used
to induce pancreatic islet cell destruction and persistent hyperglycemia, as
previously described (24) by the Animal Models of Diabetic Complications
Consortium (http://www.amdcc.org). Hyperglycemia was deﬁned as a random
blood glucose level of 300 mg/dl for 2 weeks after injection.
Measurement of biopterins. The levels of BH4 and total biopterins were
determined by high-performance liquid chromatography, as previously de-
scribed with some modiﬁcation (25).
Measurement of superoxide anions and NO. The levels of O2
–. production
in cultured cells were detected by using dihydroethidium (DHE) ﬂuorescence
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FIG. 1. Activation of AMPK by metformin attenuates diabetes-induced reduction of phospho-AMPK-Thr172 (A), GTPCH I (B), and biopterin (C)
levels and improves endothelial function. Control and diabetic mice were fed with metformin (300 mg  kg
1  day
1) for 4 weeks. Mouse aortas
were isolated and assayed for phospho-AMPK, GTPCH I, total biopterins, and BH4 levels, as described in RESEARCH DESIGN AND METHODS. The results
were obtained from ﬁve mice. *P < 0.05 versus control,
#P < 0.05 versus diabetes alone. D: ACh-induced endothelium-dependent relaxation was
assayed as described in RESEARCH DESIGN AND METHODS (n  5 per group,  P < 0.05). L-sepiapterin (10 mol/l) was added 1 h before the start of
the experiments.
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1894 DIABETES, VOL. 58, AUGUST 2009assay. NO release in cultured cells was detected by using the DAF ﬂuorescent
probe.
26S proteasome activity assay. The 26S proteasome function was mea-
sured, as described previously (26).
Reverse-transcription PCR for GTPCH I. Reverse-transcription PCR was
performed according to the manufacturer’s protocol (ThermoScript, RT-PCR
System, Invitrogen). PCR primer pairs were as described previously (27).
Assays of endothelium-dependent and endothelium-independent vasore-
laxation. Organ chamber study was performed, as described previously (28).
Statistical analysis. Data are reported as means  SE. All data were
analyzed by one- or two-way ANOVA followed by multiple t tests, and P  0.05
was considered statistically signiﬁcant.
RESULTS
Reduction in the levels of AMPK Thr172 phosphory-
lation is accompanied by a reduction of GTPCH I in
diabetic mice. Data published by our group and others
demonstrate that AMPK activation exerts beneﬁcial effects
by increasing NO bioactivity via an increase in the phos-
phorylation of eNOS and/or an increase in the anti-oxidant
potential of endothelial cells (29–31). Therefore, it was of
interest to investigate the effects of hyperglycemia/diabe-
tes on AMPK activity. As the phosphorylation of Thr172 of
AMPK is required for AMPK activity, and because AMPK-
Thr172 is closely related to AMPK activity, we ﬁrst mea-
sured the levels of phosphorylated AMPK-Thr172 in mouse
aortas isolated from mice with STZ-induced diabetes or
nondiabetic mice. As depicted in Fig. 1A, the levels of
phospho-AMPK (Thr172) were signiﬁcantly reduced in
diabetic mouse aortas relative to nondiabetic mice. In
contrast, the level of AMPK was not different in diabetic
and nondiabetic mice (Fig. 1A). Consistent with our earlier
report (9), the levels of GTPCH I were signiﬁcantly re-
duced in diabetes relative to the control group (Fig. 1B). In
contrast, the levels of eNOS were not altered in diabetic
mice or metformin-treated mice (Fig. 1B).
Activation of AMPK by metformin attenuates the
diabetes-induced reduction of GTPCH I, biopterins,
and BH4. Metformin, one of most widely used antidiabetic
drugs, markedly reduces cardiovascular incidences and
improves endothelial function in patients with diabetes
(32). Our earlier studies reported that metformin increases
NO bioactivity by activating AMPK (29). We sought to
determine whether metformin alters the diabetes-induced
reduction of GTPCH I levels. Administration of metformin
(300 mg  kg
1  day
1) for 4 consecutive weeks in the
drinking water, which did not alter the blood glucose
levels in control or diabetic mice (P  0.05, data not
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FIG. 2. Activation of AMPK is required for the AICAR/metformin-restored reduction of GTPCH I caused by high-glucose exposure in HUVECs.
HUVECs were treated with high glucose (HG) (30 mmol/l D-glucose) or hyperosmatic medium (5 mmol/l glucose plus 25 mmol/l L-glucose) for 24 h
in the presence or absence of AICAR (2 mmol/l). HUVECs were collected and assayed for the levels of P-AMPK and GTPCH I protein by Western
blot (A) and total biopterins and BH4 (B)( n  5 per group, *P < 0.05 vs. control, #P < 0.05 versus high glucose alone). C and D: Overexpression
of AMPK-DN abolishes metformin’s effects on GTPCH I, biopterins, and BH4. HUVECs were transfected with ad-GFP or ad-AMPK-DN for 24 h and
then incubated with or without metformin (2 mmol/l) for 8 h. The results are a summary of three independent experiments. *P < 0.05 versus GFP
alone, #P < 0.05 versus GFP plus metformin, NS: P > 0.05. HO, hyperosmolarity control; NG, normal glucose.
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Thr172 and GTPCH I in aortas isolated from both diabetic
and nondiabetic mice (Fig. 1A and B). Consistently, me-
formin attenuated the diabetes-induced reduction of both
biopterins and BH4 in vivo (Fig. 1C).
Metformin attenuates the diabetes-induced impair-
ment of endothelium-dependent relaxation in vivo.
We next asked whether metformin reverses the diabetes-
induced endothelial dysfunction in vivo. Endothelium-
dependent relaxation was assayed in aortas isolated
from metformin-treated diabetic mice. Compared with
nondiabetic mice, the acetylcholine (ACh)-induced en-
dothelium-dependent relaxation in diabetes was mark-
edly reduced (Fig. 1D). Further, metformin alone did not
affect the ACh-induced endothelium-dependent relax-
ation in control mice (data not shown) but abolished the
diabetes-induced impairment of endothelium-dependent
relaxation (Fig. 1D). In contrast, sodium nitroprusside
(SNP)-induced endothelium-independent relaxation was
not altered by diabetes or metformin treatment (data
not shown).
Supplementation of L-sepiapterin normalizes endo-
thelium-dependent relaxation ex vivo. L-sepiapterin, a
precursor of BH4, is converted to BH4 via a salvage
pathway (33). We next investigated whether supplementa-
tion of L-sepiapterin improved endothelial dysfunction ex
vivo. Aorta isolated from diabetic mice were incubated
with L-sepiapterin (10 	mol/l) for1hi na norgan bath. As
shown in Fig. 1D, L-sepiapterin, which did not alter the
endothelium-dependent relaxation in control mice (data
not shown), restored the ACh-induced maximal relaxation
(81.6  8.9% vs. 47.8  9.6%, P  0.05) in diabetic mice,
implying that diabetes-induced endothelial dysfunction
was likely to be because of BH4 deﬁciency.
AICAR attenuates high-glucose–induced reduction of
both GTPCH I and BH4 in HUVECs. As metformin
treatment increased the amount of GTPCH I and BH4 in
diabetic aortas, we reasoned that metformin improves
endothelial function through the inhibition of diabetes-
induced GTPCH I degradation. To test this hypothesis,
cultured HUVECs were exposed to normal glucose (5
mmol/l), high glucose (30 mmol/l D-glucose), or hyperos-
motic control (5 mmol/l D-glucose plus 25 mmol/l L-
glucose) in the presence or absence of AICAR (2 mmol/l),
an AMPK activator. High glucose did not alter AMPK and
eNOS expressions (Fig. 2A). However, consistent with the
reduction of both total biopterins and BH4 levels, the
levels of AMPK-Thr172 were markedly reduced in high-
glucose–exposed HUVECs (Fig. 2A and B). Consistent
with our previous report, neither total biopterins nor BH4
levels were altered in the hyperosmatic control group,
compared to HUVECs in normal glucose (Fig. 2B). As
expected, AICAR treatment increased the level of AMPK
phosphorylation at Thr172 in HUVECs exposed to either
normal glucose or high glucose without altering AMPK and
eNOS expressions (Fig. 2A).
We next determined the effects of high glucose on
GTPCH I. As expected, the level of GTPCH I was signiﬁ-
cantly reduced in high-glucose–exposed cells compared
with control cells (Fig. 2A). Consistently, both total biop-
terins and BH4 levels were lower in high-glucose–treated
cells than those in controls. AICAR treatment increased
the levels of both total biopterins and BH4 in HUVECs
exposed to normal glucose or high glucose (Fig. 2B).
Genetic inhibition of AMPK reduces GTPCH I in
HUVECs. As high glucose reduced the levels of both
AMPK-Thr172 and GTPCH I in HUVECs, we next asked
whether genetic inhibition of AMPK would cause a reduc-
tion in GTPCH I levels. Toward this end, AMPK was
suppressed by adenoviral overexpression of AMPK-DN.
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FIG. 3. Overexpression of AMPK-CA abolishes the reduction of GTPCH
I levels caused by high glucose (HG) in HUVECs. After 24 h of being
infected with ad-GFP or ad-AMPK-CA, HUVECs were incubated with
high glucose for an additional 24 h. After the incubation, HUVECs were
collected and assayed for GTPCH I protein (A) and total biopterins and
BH4 levels (B). *P < 0.05 versus GFP alone, #P < 0.05 versus GFP plus
high glucose, NS: P > 0.05. C: HUVECs were incubated with high
glucose for 24 h with or without AICAR. NO and ROS productions were
detected by using the ﬂuorophore 4,5-diamino-ﬂuorescein or dihydro-
ethidine ﬂuorescence, respectively. NG, normal glucose.
AMPK SUPPRESSES GTPCH I DEGRADATION
1896 DIABETES, VOL. 58, AUGUST 2009Overexpression of AMPK-DN but not GFP signiﬁcantly
reduced the levels of GTPCH I (Fig. 2C), total biopterins
(Fig. 2D), and BH4 (Fig. 2D) in HUVECs.
Genetic inhibition of AMPK blocks the effects of
metformin on GTPCH I, biopterins, and BH4. To
establish the essential role of AMPK in metformin-
enhanced GTPCH I protein levels, metformin was admin-
istered in HUVECs infected with AMPK-DN or GFP. As
shown in Fig. 2C and D, metformin increased GTPCH I,
total biopterins, and BH4 levels in GFP-infected HUVECs
but not in cells infected with AMPK-DN, implying that
AMPK is required for the metformin-induced inhibition of
GTPCH I reduction in HUVECs.
Overexpression of AMPK-CA abolishes the reduction
of GTPCH I caused by high glucose. We next deter-
mined the effects of genetic activation of AMPK on GTPCH
I, biopterins, and BH4 by over expressing a constitutively
active AMPK (AMPK-CA). As described in Fig. 3A and B,
overexpression of AMPK-CA but not GFP abolished the
high-glucose–induced reduction of GTPCH I (Fig. 3A),
biopterins (Fig. 3B), and BH4 levels (Fig. 3B).
We next determined if AMPK activation altered eNOS-
derived NO/ROS production in response to high glucose.
As expected, high glucose signiﬁcantly increased ROS
while it suppressed NO production in HUVEC (Fig. 3C). As
expected, AICAR signiﬁcantly increased NO release but
decreased ROS, implying that increased GTPCH I and
consequent BH4 increase might normalize the function of
eNOS in HUVEC.
GTPCH I mRNA is not involved in the AMPK-induced
upregulation of GTPCH I protein. Increased levels of
GTPCH I could be because of the transcriptional activa-
tion of the GTPCH I gene or attributable to the decrease of
GTPCH I protein degradation. We ﬁrst determined
whether AMPK activation altered GTPCH I mRNA levels in
HUVECs. As shown in Fig. 4A, treatment of HUVECs with
AICAR (2 mmol/l) for 24 h did not alter the levels of
GTPCH I mRNA in HUVECs exposed to normal glucose or
high glucose. In addition, neither cycloheximide nor acti-
nomycin D altered the levels of GTPCH I protein caused by
AICAR or metformin (Fig. 4B). Neither cycloheximide nor
actinomycin D altered the high-glucose–induced reduction of
GTPCH I levels in HUVECs (Fig. 4B). Taken together, our
data suggest that the increase of GTPCH I protein levels
caused by AMPK activation is independent of transcriptional
activation of the GTPCH I gene.
26S proteasome mediates the reduction of GTPCH I
levels in high-glucose–treated HUVECs. The levels of
GTPCH I protein are controlled by both GTPCH I synthesis
and GTPCH I degradation. Our earlier study demonstrated
that high glucose activates the 26S proteasome, resulting
in the enhanced degradation of GTPCH I in endothelial
cells (9). Co-administration of MG132 (0.5 	mol/l, 4 h), a
potent proteasome inhibitor, abolished the high-glucose–
induced reduction of GTPCH I levels (Fig. 5A), conﬁrming
that the alteration of GTPCH I levels was because of the
activation of the 26S proteasome.
AMPK activation suppresses the increase of 26S pro-
teasome activity caused by high glucose. We next inves-
tigated the effects of AMPK activation on 26S proteasome
activity in HUVECs. As shown in Fig. 5B, high glucose
exposure signiﬁcantly increased 26S proteasome activity,
whereas AICAR treatment signiﬁcantly reduced 26S protea-
some activity in cells exposed to normal or high glucose.
We next determined whether genetic activation of AMPK
withAMPK-CAwouldalter26SproteasomeactivityinHUVECs.
Infection of AMPK-CA but not GFP reduced 26S proteasome
activity in control cells (Fig. 5C). In addition, AMPK-CA but not
GFP abolished high-glucose–enhanced 26S proteasome activity
in HUVECs. These results suggest that AMPK functions as a
physiological suppressor for 26S proteasome-mediated GTPCH
I degradation in HUVECs.
Next, we examined whether activation of AMPK affects
the ubiquitination of GTPCH I in high-glucose–treated
HUVECs. HUVEC were incubated with high glucose for
24 h with or without AICAR. After the incubation, GTPCH
I was immunoprecipitated by the speciﬁc antibody against
GTPCH I. GTPCH I ubiquitination was identiﬁed in West-
ern blotting by using the antibody against ubiquitinated
protein. As shown in Fig. 5D, AICAR alone signiﬁcantly
increased the level of ubiquitination GTPCH I in HUVEC.
Conversely, high glucose signiﬁcantly decreased the ubiq-
uitination GTPCH I in HUVEC (Fig. 5D). Interestingly,
co-administration of high glucose with AICAR abolished
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GTPCH I in HUVEC (Fig. 5D).
AMPK2 depletion increases 26S proteasome activ-
ity but reduces the levels of GTPCH I, biopterins, and
BH4 in isolated aortas. We next determined the effects
of AMPK depletion on 26S proteasome activity and the
levels of GTPCH I, biopterins, and BH4 in isolated mice
aortas. We used AMPK1o r- 2 knockout mice. As shown
in Fig. 6A, relative to genetic control mice, C57BL6,
GTPCH I protein levels were markedly lower in
AMPK2
/ but not in AMPK1
/ mice aortas, implying
that AMPK2 subunit plays a key role in the regulation of
GTPCH I protein expression. MG132 treatment (0.5
	mol/l, 4 h), which only slightly increased GTPCH I levels
in control and AMPK1
/ mice, signiﬁcantly increased
GTPCH I levels in the aortas of AMPK2
/ mice.
The deﬁciency of GTPCH I contributes to the lack of
BH4 and eNOS uncoupling in endothelial cells (9,34). We
determined the levels of both total biopterins and BH4 in
wild-type (WT) and AMPK2
/ mice aortas. As shown in
Fig. 6B, both total biopterins and BH4 levels were lower in
AMPK2
/ mice aortas than those in WT mice aortas
(P  0.05), but injection of AMPK2
/ mice with MG132
(5 mg  kg
1  day
1 for 2 days, intraperitoneally) reversed
the effects on both total biopterins and BH4 levels in
aortas.
We further detected proteasome activity in AMPK2
/
mice aortas. As shown in Fig. 6C, the 26S proteasome
activity was greater in AMPK2
/ mice than that in WT
mice. Metformin treatment suppressed 26S proteasome
activity in WT mice, but not in AMPK2
/ mice, implying
that AMPK2 was required for metformin’s effects on 26S
proteasome in vivo.
Inhibition of the 26S proteasome with MG132 or
supplementation of BH4 with L-sepiapeterin restores
endothelium-dependent relaxation in the aortas of
AMPK2
/ mice. To establish a cause-effect relation-
ship between proteasome-dependent GTPCH I degrada-
tion and impaired endothelium-dependent relaxation in
AMPK2
/ mice, we injected AMPK2
/ mice with
MG132 (5 mg  kg
1  day
1 for 2 days, intraperitoneally) or
L-sepiapterin (10 mg  kg
1  day
1 for 7 days, intraperito-
neally). After the treatments, mouse aortas were isolated
and assayed for endothelium-dependent and endothelium-
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relaxation (Emax) induced by ACh is 83.63  7.60% in WT
aortas. However, Emax of ACh is only 60.9  5.5 in
AMPK2
/ aortas (P  0.05 vs. WT). MG132 did not alter
the ACh-induced endothelium-dependent relaxation in WT
mice but improved the relaxation in AMPK2
/ mice. As
shown in Fig. 7B, L-sepiapterin also mitigated the decrease
of ACh-induced Emax in AMPK2
/ mice (73.82  9.50%
vs. AMPK2
/, P  0.05). SNP-induced, endothelium-
independent relaxations in aortas were comparable among
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DIABETES, VOL. 58, AUGUST 2009 1899three groups (data not shown). Taken together, these
results support the idea that the impaired endothelial
function of AMPK2
/ mice is because of proteasome-
dependent GTPCH I degradation.
DISCUSSION
The major ﬁnding of this study is that AMPK inhibition in
diabetes or genetic depletion of AMPK leads to abnormal
26S proteasome activity, resulting in the accelerated deg-
radation of GTPCH I, a key enzyme in the de novo
synthesis of BH4. The regulation of GTPCH I function can
be achieved at both the mRNA and protein levels (stability,
activity, and modiﬁcation) (27). Here, we found that AMPK
regulates GTPCH I protein stability in endothelial cells by
inhibiting the 26S proteasome. This conclusion is sup-
ported by several ﬁndings: First, inhibition of the protea-
some by MG132 produced suppressive effects similar to
AMPK activation on high-glucose–triggered GTPCH I deg-
radation. Second, inhibition of AMPK by high glucose or
knockout of AMPK2 increased 26S proteasome activity.
Third, overexpression of AMPK-CA or AICAR abolished
high-glucose–induced upregulation of the 26S proteasome
activity. Consistent with our result, Moreno et al. and
Viana et al. have reported that two AMPK activators,
AICAR and A769662, inhibit 26S proteasome activity in WT
mouse embryonic ﬁbroblast cells and human skin ﬁbro-
blast cells through AMPK-dependent and independent
mechanisms (22,35). Fourth, earlier studies by our group
and others have demonstrated that GTPCH I protein is
ubiquitinated and degraded by the 26S proteasome system
under conditions of hyperglycemia or 4-hydroxy-2-nonenal
(9,34). Finally, deletion of AMPK2 increased the ubiquiti-
nation of GTPCH I in the presence of MG132 in HUVECs
and mice aortas. However, how AMPK activation sup-
presses 26S proteasomes remains largely unknown and
warrants further investigation.
Metformin, which was shown recently to exert its
therapeutic effect in diabetes by activating AMPK (36), is
known to improve vascular functions and to dramatically
reduce cardiovascular end points and mortality for dia-
betic patients in large-scale clinical trials (32). Increasing
evidence suggests that AMPK activation leads to a series
of beneﬁcial metabolic consequences, including augmen-
tation of fatty acid oxidation and glucose uptake in skel-
etal muscle, as well as inhibition of glucose production,
lipogenesis, and cholesterol synthesis in the liver. In
addition to producing beneﬁcial metabolic effects, AMPK
may regulate endothelial function. There are abundant
data to suggest that AMPK is critical for eNOS activation
by VEGF, shear stress, estradio, adiponectin, and antidia-
betic drugs, including metformin (37). AMPK-dependent
eNOS activation is generally ascribed to increased phos-
phorylation of eNOS at Ser1177 by AMPK, increased
association of HSP90 with eNOS, or both. As BH4 is an
essential cofactor for the NO synthetic activity of eNOS
and GTPCH I deﬁciency uncouples eNOS (producing
superoxide anions instead of NO), AMPK-mediated inhibi-
tion of GTPCH I degradation might be essential for main-
taining the physiological functions of eNOS. Thus, this
study is the ﬁrst to uncover a novel mechanism (Fig. 7C)
by which AMPK activation prevents or ameliorates vascu-
lar endothelial function by suppressing proteasome-
dependent GTPCH I degradation. Notably, a recent study
of obese rats (38) demonstrated that decreased AMPK
activity in aortic endothelium is closely associated with
impaired endothelium-dependent relaxation, as well as an
increased number of apoptotic endothelial cells, raising
the possibility that a decline in AMPK activity contributes
to endothelial dysfunction (37). AMPK could be an impor-
tant target in treating cardiovascular complications in
diabetes.
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